Skip to content
Screener

GeneDx Holdings WGS Q4 2025 Annual earnings

Reported February 23, 2026 · Before market open

Revenue$121.0MBeat by $675.6K
EPS$0.14Beat by $0.03
Revenue estimate$120.3M
EPS estimate$0.11

Next report

Oct 27, 2026 (in a month)
Revenue estimate$123.0M
EPS estimate$0.07

Financials

Q4 2025

Income statement

See full
Revenue$121.0M+26.5%
Gross profit$84.3M+27.3%
Operating income-$14.2M—
Net income-$17.7M—
EPS (diluted)-$0.61—

Balance sheet

See full
Cash & equivalents$106.0M+23.0%
Total debt$113.2M-3.6%
Total equity$308.2M+25.7%
Total assets$523.7M+24.9%

Cash flow

See full
Operating cash flow-+100%
CapEx$4.3M+42.5%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.76B+78.0%
Enterprise value$3.77B+75.8%
P/S8.8×+1.9×

Profitability

See full
Gross margin69.7%+6.1pp
Operating margin-3.1%—
Net margin-4.9%—

Returns & leverage

See full
Return on equity-7.6%—
Debt / equity0.4×-0.1×
Current ratio2.5×-1.1×

FAQ

When did GeneDx Holdings report Q4 2025 earnings?
GeneDx Holdings (WGS) reported Q4 2025 earnings on February 23, 2026 before market open.
What were GeneDx Holdings's Q4 2025 revenue and EPS?
GeneDx Holdings reported revenue of $121.0M and eps of $0.14 for Q4 2025.
Did GeneDx Holdings beat estimates in Q4 2025?
Revenue beat the consensus estimate of $120.3M by $675.6K. EPS beat the consensus estimate of $0.11 by $0.03.
How did GeneDx Holdings's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 26.5% from $95.6M a year earlier and eps declined 80.0% from $0.70.
Where can I find GeneDx Holdings's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001818331-26-000014) and the 10-K periodic report (0001818331-26-000015) directly on SEC EDGAR. The filing index links above go to sec.gov.